Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.100 GeneticVariation disease BEFREE CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report. 16048458 2005
Entrez Id: 10008
Gene Symbol: KCNE3
KCNE3
0.010 GeneticVariation disease BEFREE A KCNE3 T4A mutation was identified in a Japanese patient presenting Brugada-pattern ECG and NMS. 22987075 2012
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.100 GeneticVariation disease BEFREE A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. 21749835 2012
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.060 GeneticVariation disease BEFREE A recent genetic study suggested an association between NMS and the I A polymorphism in the dopamine D2 receptor (DRD2 ) gene. 12605103 2003
Entrez Id: 5286
Gene Symbol: PIK3C2A
PIK3C2A
0.010 GeneticVariation disease BEFREE A single base substitution, C7278T, was detected in one patient whose serum CPK level was repetitively elevated, but his other major symptoms did not fulfil the clinical criteria for NMS. 8981316 1996
Entrez Id: 5973
Gene Symbol: RENBP
RENBP
0.010 Biomarker disease BEFREE A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. 28144982 2017
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.100 Biomarker disease BEFREE A total of 29 patients appeared to have developed NMS as a result of having taking CYP2D6 substrates. 17701031 2007
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.100 GeneticVariation disease LHGDN A total of 29 patients appeared to have developed NMS as a result of having taking CYP2D6 substrates. 17701031 2007
Entrez Id: 100379198
Gene Symbol: ECT
ECT
0.020 Biomarker disease BEFREE All patients received bitemporal ECT after failed pharmacotherapy for NMS. 31022041 2019
Entrez Id: 100379198
Gene Symbol: ECT
ECT
0.020 Biomarker disease BEFREE All patients received bitemporal ECT after failed pharmacotherapy for NMS. 31764444 2019
Entrez Id: 6261
Gene Symbol: RYR1
RYR1
0.030 GeneticVariation disease BEFREE Genetic analysis of ryanodine receptor 1 gene and carnitine palmitoyltransferase II gene: an autopsy case of neuroleptic malignant syndrome related to vegetamin. 19269221 2009
Entrez Id: 1376
Gene Symbol: CPT2
CPT2
0.010 GeneticVariation disease BEFREE Genetic analysis of ryanodine receptor 1 gene and carnitine palmitoyltransferase II gene: an autopsy case of neuroleptic malignant syndrome related to vegetamin. 19269221 2009
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.060 GeneticVariation disease BEFREE Genetic association studies have sought to identify polymorphisms influencing susceptibility to NMS, especially with respect to the dopamine D(2) receptor, serotonin receptor, and cytochrome p450 2D6. 12749726 2003
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.100 Biomarker disease BEFREE Genetic association studies have sought to identify polymorphisms influencing susceptibility to NMS, especially with respect to the dopamine D(2) receptor, serotonin receptor, and cytochrome p450 2D6. 12749726 2003
Entrez Id: 107987479
Gene Symbol: LOC107987479
LOC107987479
0.010 Biomarker disease BEFREE Genetic association studies have sought to identify polymorphisms influencing susceptibility to NMS, especially with respect to the dopamine D(2) receptor, serotonin receptor, and cytochrome p450 2D6. 12749726 2003
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.100 GeneticVariation disease BEFREE In addition, genotyping of CYP2D6 might be considered in patients with symptoms suggestive of drug toxicity who are treated with neuroleptics metabolized via the CYP2D6 pathway, as carriage of one or more non-functional alleles may increase the risk for adverse reactions, such as NMS. 24253372 2014
Entrez Id: 6261
Gene Symbol: RYR1
RYR1
0.030 GeneticVariation disease BEFREE In this study, we analyzed possible mutations of the RYR1 gene in 11 psychiatric patients suspected at autopsy to have died of NMS. 19931341 2010
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.060 GeneticVariation disease LHGDN Our previous study has suggested that the TaqI A polymorphism of dopamine D2 receptor gene (DRD2) is associated with the predisposition to neuroleptic malignant syndrome (NMS). 12555236 2003
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.060 GeneticVariation disease BEFREE Our previous study has suggested that the TaqI A polymorphism of dopamine D2 receptor gene (DRD2) is associated with the predisposition to neuroleptic malignant syndrome (NMS). 12555236 2003
Entrez Id: 6261
Gene Symbol: RYR1
RYR1
0.030 GeneticVariation disease BEFREE Our results do not support the association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated with malignant hyperthermia. 8981316 1996
Entrez Id: 255239
Gene Symbol: ANKK1
ANKK1
0.010 GeneticVariation disease LHGDN Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. 12555236 2003
Entrez Id: 6872
Gene Symbol: TAF1
TAF1
0.010 Biomarker disease BEFREE SNORD115-TAF1 and SNORD-DPM2 dysfunction introduce possible clues to the parkinsonism and increased creatinine phosphokinase in NMS, while abnormalities of SNORD115-RALGPS1 suggest links to both anti-NMDAR encephalitis and the proven predisposing catatonic SHANK3 gene. 29523295 2018
Entrez Id: 8818
Gene Symbol: DPM2
DPM2
0.010 Biomarker disease BEFREE SNORD115-TAF1 and SNORD-DPM2 dysfunction introduce possible clues to the parkinsonism and increased creatinine phosphokinase in NMS, while abnormalities of SNORD115-RALGPS1 suggest links to both anti-NMDAR encephalitis and the proven predisposing catatonic SHANK3 gene. 29523295 2018
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.060 GeneticVariation disease BEFREE Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. 7573176 1995
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.100 GeneticVariation disease BEFREE The aetiology of neuroleptic malignant syndrome is not explainable in terms of CYP2D6 gene mutations. 9323326 1997